FDA clears AI-powered cardiac platform for pediatric patients

Cardilogs, a Paris-based healthcare technology company, has received FDA clearance to use its AI-powered cardiac diagnostics platform for pediatric cardiology patients.

According to the company, the extended use authorization was granted based on analysis of the company’s latest deep learning algorithm, which was originally approved by the FDA in 2017.

“The fact that our algorithm continues to improve and is proven to provide clinically consistent results across all age groups means that clinicians can now use our breakthrough technology with the utmost confidence, even in children under the age of 18,” said Yann Fleureau, CEO from cardiologs. and co-founder, said in a prepared statement.

Comments are closed.